Y-Intercept (HK)’s Abivax ABVX Stock Holding History

Y-Intercept (HK)’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-54,993	Closed	-$7.42M	–	1502
2025 Q4	$7.42M	Buy	+54,993	New	+$6M	0.17%	121

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Y-Intercept (HK)'s ABVX Position: Q1 2026 in Review

Y-Intercept (HK) sold out of Abivax (ABVX) in Q1 2026, closing a stake of 54,993 shares — an estimated $7.42M sold.

Y-Intercept (HK) first reported a position in ABVX in Q4 2025 and held it in 1 quarter. The position peaked at $7.42M in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

Y-Intercept (HK) reported no remaining Abivax position as of Q1 2026 after selling out during the quarter.
Y-Intercept (HK) sold 54,993 Abivax shares in Q1 2026, an estimated $7.42M.
Y-Intercept (HK) first reported a position in Abivax in Q4 2025 and held it in 1 quarter.
Y-Intercept (HK)'s Abivax position peaked at $7.42M in Q4 2025.
254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Y-Intercept (HK)'s 13F filing for Q1 2026, filed 27 Apr 2026.